Skip to main content
Matthew Freedman, MD, Oncology, Boston, MA

MatthewLFreedmanMD

Oncology Boston, MA

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Dr. Freedman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Freedman's full profile

Already have an account?

  • Office

    44 Binney St
    Dana 710-C
    Boston, MA 02115
    Phone+1 617-582-8598

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2002
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 1996 - 1998
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1996

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2011

Publications & Presentations

PubMed

Press Mentions

  • Prostate Cancer Metastasis Linked to Revival of Dormant Molecular Program
    Prostate Cancer Metastasis Linked to Revival of Dormant Molecular ProgramJuly 19th, 2020

Grant Support

  • Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-makingDANA-FARBER CANCER INST2025–2030
  • Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
  • Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2022–2027
  • Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2022–2027
  • Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
  • Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
  • Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
  • Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesDANA-FARBER CANCER INST2021–2026
  • P-2: Genetic And Clinical Characterization Of The 8q24 Prostate Cancer Risk LocusNational Cancer Institute2010–2011
  • Elucidating Loci Involved In Prostate Cancer SuceptibilityNational Cancer Institute2010–2011
  • Discovery, Biology And Risk Of Inherited Variants In Breast CancerNational Cancer Institute2010–2011
  • Genetic And Clinical Characterization Of The 8q24 Prostate Cancer Risk LocusNational Cancer Institute2007–2009
  • FINE Mapping And Characterization Of The 8q24 Prostate Cancer Risk LocusNational Cancer Institute2007–2009